Company
Platform
Insights
Nearly all cancer clinical trials enroll patients based on coarse biomarkers that don’t actually predict response. We believe our models can identify responders far more accurately.
95% percent of cancer drugs fail their clinical trials. We believe a significant fraction of those drugs actually work on the right patient population.
The oncology field has focused on the same set of a dozen cancer targets for decades. We believe our platform is capable of discovering hundreds more.














